Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. 2005

Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
Department of Internal Medicine 1, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Oita, 879-5593, Japan.

OBJECTIVE To compare the effects of combined therapy of an angiotensin II receptor blocker (ARB; valsartan) and an angiotensin converting enzyme inhibitor (ACEI; perindopril) on blood pressure (BP), metabolic profiles, plasma brain natriuretic peptide (BNP) levels, echocardiographic findings, and aortic pulse wave velocity (PWV) with those of respective monotherapy in never-treated patients with essential hypertension. METHODS This was a prospective randomized trial, in which there were 31 patients with essential hypertension and left ventricular hypertrophy (LVH) who visited the outpatient clinic of Oita Red Cross Hospital (14 women and 17 men; mean+/-SD age, 59+/-5 years). Each patient was randomly assigned to receive valsartan (160 mg/day, V group, n=10), perindopril (8 mg/day, P group, n=11), or a combination of valsartan (80 mg/day) and perindopril (4 mg/day, V+P group, n=10) for 40 weeks. Ambulatory BP monitoring (ABPM), echocardiographic findings, metabolic findings, plasma BNP levels, and brachial-ankle PWV (baPWV) were evaluated before and after the 40-week therapy. RESULTS The baseline and post-therapeutic BP levels were similar among the three groups. At baseline ABPM, non-dipping was observed in 80, 82, and 80% in the V, P, and V+P groups, respectively. Each 40-week therapy regimen comparably reduced ABP. The plasma BNP levels (P<0.0001 for each), left ventricular mass index (LVMI) (P<0.01 for each), and PWV values (P<0.0001 for each) were also reduced. However, when compared with either V or P group, the percentage reduction in LVMI (P<0.05 and P<0.005, respectively), BNP (P<0.05 for each), and baPWV values (P<0.005 and P<0.001, respectively) was greater in the V+P group. CONCLUSIONS Our findings suggest that, when compared with each monotherapy, perindopril and valsartan combination therapy exerts greater beneficial effects regarding the regression of LVH, reduction in BNP, and improvement of PWV in a selected group of essential hypertensive patients with LVH and high prevalence of non-dipping patterns.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068756 Valsartan A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. CGP 48933,Diovan,Kalpress,Miten,N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine,Nisis,Provas,Tareg,Vals,48933, CGP

Related Publications

Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
January 2015, Bratislavske lekarske listy,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
January 2003, Current medical research and opinion,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
January 2004, Advances in therapy,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
January 2002, Blood pressure,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
June 1984, La Revue de medecine interne,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
December 1994, Clinical science (London, England : 1979),
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
September 1995, Chinese medical journal,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
August 1999, Circulation,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
November 1998, Circulation,
Futoshi Anan, and Naohiko Takahashi, and Tatsuhiko Ooie, and Kunio Yufu, and Masahide Hara, and Mikiko Nakagawa, and Hidetoshi Yonemochi, and Tetsunori Saikawa, and Hironobu Yoshimatsu
August 1999, Circulation,
Copied contents to your clipboard!